Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients
Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients
复制标题
家族性地中海热与类风湿关节炎患者血清炎性细胞因子浓度比较
DOI：
10.1080/03009742.2017.1363281
复制
发表时间：
2017
影响因子：
2.1
通讯作者：
Kawakami A
中科院分区：
文献类型：
--
作者：
Koga T;Kawashiri S-y;Migita K;Sato S;Umeda M;Fukui S;Nishino A;Nonaka F;Iwamoto N;Ichinose K;Tamai M;Nakamura H;Origuchi T;Ueki Y;Masumoto J;Agematsu K;Yachie A;Eguchi K;Kawakami A
类风湿性关节炎（RA）的临床特征是慢性炎症和关节破坏。一些对RA患者血清中细胞因子的分析发现，炎症细胞因子如白细胞介素6 （IL-6）和肿瘤坏死因子-α (TNF-α)升高(1)，这些分子是生物制剂的治疗靶点。抑制TNF-α和IL-6已被证明对RA患者有效(1)。家族性地中海热（FMF）是一种典型的遗传性自身炎症性疾病，临床表现为周期性发热伴关节炎和浆膜炎。与RA患者类似，FMF患者血清中炎症细胞因子水平升高，我们已经确定了特定细胞因子作为FMF发作的组合诊断生物标志物(2)。虽然在RA患者中使用的生物制剂，如TNF抑制剂和IL-6抑制剂，已被认为对FMF有效(3)，但FMF发病机制中涉及的确切细胞因子网络和细胞因子浓度可能与RA不同，这些生物制剂治疗FMF的最佳剂量尚未确定。在本研究中，为了澄清FMF和RA患者细胞因子谱的差异，并估计生物制剂的适当剂量，我们比较了FMF患者的血清细胞因子浓度，FMF患者的外显子2、3和/或10突变
Rheumatoid arthritis (RA) is clinically characterized by chronic inflammation and joint destruction. Several analyses of cytokines in the serum of RA patients have identified that inflammatory cytokines such as interleukin 6 (IL-6) and tumour necrosis factor-α (TNF-α) are elevated (1), and that these molecules are therapeutic targets for biological agents. The inhibition of TNF-α and IL-6 has been shown to be effective in RA patients (1). Familial Mediterranean fever (FMF) is a typical hereditary autoinflammatory disease, clinically characterized by periodic fever with arthritis and serositis. Similarly to RA patients, FMF patients exhibit elevated levels of inflammatory cytokines in the serum, and we have identified specific cytokines as combinational diagnostic biomarkers in attacks of FMF (2). Although biological agents used in RA patients, such as TNF inhibitors and IL-6 inhibitors, have been suggested for their effectiveness in FMF (3), the exact cytokine networks involved in pathogenesis and the concentrations of cytokines in FMF may be different from those in RA, and the optimal dose of these biological agents for the treatment of FMF has not been determined. In the present study, to clarify differences in the cytokine profiles of FMF and RA patients and to estimate the adequate dose of biological agents, we compared the serum cytokine concentrations of FMF patients with mutations in exon 2, 3, and/or 10 of the